Comparative analysis of antibody responses to BNT162b2, ChAdOx1, and CoronaVac vaccines in the Albanian population over the pandemic years 2021 to 2022

Clin Exp Vaccine Res. 2024 Jan;13(1):63-67. doi: 10.7774/cevr.2024.13.1.63. Epub 2024 Jan 31.

Abstract

This repeated cross-sectional study with two independent sample populations compared the antibody response to severe acute respiratory syndrome coronavirus 2 vaccines in Albania in July-August 2021 and 2022. In 2021, it found higher anti-spike-1 seropositivity and antibody levels in fully vaccinated individuals, especially with BNT162b2 and ChAdOx1 and to a lesser degree with CoronaVac. By 2022, all single-dose recipients showed high antibody responses, suggesting natural infection-enhanced immunity. The study indicates a significant evolution in the antibody response to different coronavirus disease 2019 vaccines and suggests that a single vaccine dose, coupled with natural infection, might suffice to maintain adequate immunity levels in an endemic scenario.

Keywords: Albanian people; Anti-nucleoprotein immunoglobulin G; Anti-spike-1 immunoglobulin G; COVID-19 vaccines; SARS-CoV2 antibodies.